阿托伐他汀钙联合水飞蓟宾治疗非酒精性脂肪肝的临床效果  

Clinical effect of Atorvastatin Calcium combined with Silibinin in the treatment of non-alcoholic fatty liver disease

作　　者：贺小军[1] 杨振宇[1] 杜锡林[1] 谭凯[1] 杨涛[1] 鲁建国[1] 

机构地区：[1]第四军医大学唐都医院普通外科,陕西西安710038

出　　处：《中国医药导报》2017年第14期123-125,130,共4页China Medical Herald

摘　　要：目的探讨阿托伐他汀钙联合水飞蓟宾治疗非酒精性脂肪肝的临床效果。方法选取2015年7月~2016年3月就诊于第四军医大学唐都医院的非酒精性脂肪肝患者170例,采用随机数字表法将其分为观察组和对照组,各85例。观察组在常规治疗的基础上联合应用阿托伐他汀钙20 mg,1次/d,水飞蓟宾70 mg,3次/d;对照组在常规治疗的基础上单纯应用水飞蓟宾70 mg,3次/d,连续治疗24周。比较两组治疗前后肝功能及血脂水平改善情况,并通过影像学检查脂肪肝改善程度。结果两组治疗后谷草转氨酶(AST)、谷丙转氨酶(ALT)均较治疗前明显降低,差异有统计学意义(P<0.05);治疗后观察组AST、ALT水平稍低于对照组,但差异无统计学意义(P>0.05)。两组治疗后三酰甘油(TG)、总胆固醇(TC)水平均较治疗前明显降低,且观察组治疗后TG、TC水平均明显低于对照组,差异均有统计学意义(均P<0.05)。治疗后观察组CT值明显高于对照组,差异有统计学意义(P<0.05)。结论阿托伐他汀钙联合水飞蓟宾治疗非酒精性脂肪肝可有效改善患者的肝功能和血脂水平,并减轻脂肪肝严重程度。Objective To investigate the clinical effect of Atorvastatin Calcium combined with Silibinin in the treatment of non-alcoholic fatty liver disease. Methods One hundred and seventy patients with non-alcoholic fatty liver disease treated in Tarrgdu Hospital of the Fourth Military Medical University from July 2015 to March 2016 were selected and divided into observation group and control group by random number table method, with 85 cases in each group. On basis of routine treatment, the observation group was added with Atorvastatin Calcium 20 mg, once a day, Silibinin 70 rag, 3 times/d; on basis of routine treatment, the control group was only applied with Silibinin 70 mg, 3 times/d, for 24 weeks. The improvement of liver function and serum lipid levels of the two groups before and after treatment was compared, and the improvement of fatty liver was detected by image examination. Results After treatment, the levels of aspartate aminotransferase （ALT） and alanine transaminase （AST） in observation group were significantly lower than those before treatment, the differences were statistically significant （P 〈 0.05）; after treatment, the levels of ALT and AST in observation group were lower than those of control group, but the differences were not statistically significant （P 〉 0.05）. After treatment, the levels of triacylglycerol （TG） and total cholesterol （TC） were all significantly lower than those before treatment, and the levels of TG and TC in observation group were lower than those of control group, the differences were all statistically significant （all P 〈 0.05）. The CT value of observation group after treatment was higher than that of control group, the difference was statistically significant （P 〈 0.05）. Conclusion Atorvastatin Calcium combined with Silibinin in treatment of non-alcoholic fatty liver disease can effectively improve the liver function and serum lipid levels, and reduce the severity of fatty liver.

关 键 词：非酒精性脂肪肝 阿托伐他汀钙 水飞蓟宾 

分 类 号：R575.2[医药卫生—消化系统]